ERBB2 and neoplasm: Namely, regarding participants 2 and 3, with HER2 positive tumors as an initial diagnosis, the 18FDG PET/CT—performed before and after neoadjuvant chemotherapy—showed both decreased tumor size and metabolic activity after chemotherapy (data not shown).